The Pharmacogenomics of Anti-Hypertensive Therapy
Hypertension is a major public health problem, but measures to reduce blood pressure and thus cardiovascular risk are complicated by the high prevalence of treatment resistance, despite the availability of multiple drugs. Drug side-effects contribute considerably to suboptimal blood pressure control...
Main Authors: | Sandosh Padmanabhan, Laura Paul, Anna F. Dominczak |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2010-06-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | http://www.mdpi.com/1424-8247/3/6/1779/ |
Similar Items
-
Amlodipine Vs. hydrochlorothiazide: is there any disparity in its antihypertensive effect or not?
by: Venu Gopal Jonnalagadda, et al.
Published: (2017-12-01) -
Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
by: Jordan Loader, et al.
Published: (2022-06-01) -
Hypertension and COVID-19: Updates from the era of vaccines and variants
by: Sowmya Swamy, et al.
Published: (2022-03-01) -
Chlorthalidone, not hydrochlorothiazide, is the right diuretic for comparison
by: Ravi Tejraj Mehta, et al.
Published: (2018-03-01) -
The Evolving Role of Calcium Channel Blockers in Hypertension Management: Pharmacological and Clinical Considerations
by: Kamryn E. Jones, et al.
Published: (2024-06-01)